A Cedars-Sinai analysis group is within the pre-clinical phases of creating a expertise that harnesses intermittent ultraviolet (UV) A light-weight for treating viruses and micro organism. The expertise has not been examined or used on sufferers. Cedars-Sinai has filed for patents associated to the expertise and has signed a licensing settlement with Aytu BioScience with the goal of doubtless enabling near-term use as a COVID-19 intervention for critically unwell, intubated sufferers.
